The European Medicine Agency’s human medicines committee, the CHMP, has delivered a positive opinion on Bristol Myers Squibb Company/bluebird bio’s CAR T-cell therapy, Abecma (idecabtagene vicleucel), the first cell-based gene therapy for patients with multiple myeloma.
EMA OKs BMS/bluebird bio’s CAR-T Abecma For Multiple Myeloma
Other EU Recommendations Include Astellas’s Roxadustat & BioMarin’s Vosoritide
A gene therapy for multiple myeloma, a new drug for achondroplasia, and the first biosimilar version of Roche’s Lucentis are among eight products recommended for EU marketing authorization this week.
